T1	Participants 335 408	level of adenosine deaminase (ADA) in patients with chronic schizophrenia
T2	Participants 608 662	parallel groups of patients with chronic schizophrenia
T3	Participants 664 780	Eligible participants in the study were 51 patients with chronic schizophrenia with ages ranging from 20 to 45 years
T4	Participants 782 892	All participants were inpatients, in the active phase of illness, and met DSM-IV-TR criteria for schizophrenia
T5	Participants 894 1031	Patients were randomly allocated (17 patients in each group) to risperidone (6 mg/day) or haloperidol 15 mg/day or clozapine (300 mg/day)
